Prescribing information



Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

In this webinar, Professor Miriam Wittmann and Dr Helena Marzo-Ortega discuss the need for joint plaque psoriasis (PsO) and psoriatic arthritis (PsA) clinics and offer perspectives on how joint dermatology–rheumatology clinics can be established within a Trust, and what benefits they can offer. They then further discuss their experiences when setting up a joint clinic.


Click here for Cosentyx® (secukinumab) prescribing information


Want to be notified of upcoming webinars?

Click the button below


BAD, British association of dermatology; BADBIR, British Association of Dermatologists Biologics and Immunomodulators Register; DMARD, disease-modifying anti-rheumatic drug; NSAID, non-steroidal anti-inflammatory drug; MTX, methotrexate.

Rate this content: 
No votes yet
UK | June 2021 | 131432

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]